Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 4/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | TET3 | O43151 | 1/20 | 0.30 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880563 | 0.84 | — | — | |
| SCHEMBL2203074 | 0.82 | GRIK1 (0.35) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL3240320 | 0.79 | ALDH1A1 (0.39) | GRIK1GRIK2TET2GRIA2GRIA4 | |
| SCHEMBL9337786 | 0.77 | TET2 (0.32) | GRIK1TET2 | |
| Methacrylic Acid SCHEMBL8161913 | 0.77 | GRIK1 (0.33) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| Acrylic Acid SCHEMBL9625364 | 0.76 | ALOX15 (0.36) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9152270 | 0.76 | GRIK1 (0.32) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL2545650 | 0.76 | GRIK1 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9280588 | 0.75 | APEX1 (0.36) | GRIK1TSHR | |
| SCHEMBL8820421 | 0.74 | CA2 (0.35) | GRIK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173284-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | US | claimed |
| US-20240091201-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | AustinPx, LLC (US) | 2024-03-21 | — | — | US | claimed |
| US-11878005-B2 | Formulations of deferasirox and methods of making the same | AustinPx, LLC (US) | 2024-01-23 | — | — | US | claimed |
| US-20230218533-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-13 | — | — | US | claimed |
| US-20230167181-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURE USING THERMALLY CONDUCTIVE EXCIPIENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | US | claimed |
| WO-2023086832-A1 | METHODS OF PREPARING DOSAGE FORMS USING 3D PRINTING CONTAINING AMORPHOUS SOLID DISPERSIONS | BOARD OF REGENTS, THE UNIVERSITY OFTEXAS SYSTEM (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4164618-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | Board of Regents, The University of Texas System (US) | 2023-04-19 | — | — | EP | claimed |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | claimed |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2022-08-23 | — | — | US | claimed |
| WO-2021252793-A1 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-16 | — | — | WO | claimed |
| US-20170333404-A1 | IMPROVED FORMULATIONS OF VEMURAFENIB AND METHODS OF MAKING THE SAME | DISPERSOL TECHNOLOGIES, LLC (US) | 2017-11-23 | — | — | US | claimed |
| WO-2017196712-A1 | IMPROVED DRUG FORMULATIONS | DISPERSOL TECHNOLOGIES, LLC (US) | 2017-11-16 | — | — | WO | claimed |
| WO-2017075576-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | claimed |
| US-9622979-B2 | Multilayered dosage form | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-04-18 | — | — | US | claimed |
| US-20170027911-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | DISPERSOL TECHNOLOGIES, LLC (US) | 2017-02-02 | — | — | US | claimed |
| WO-2016205658-A1 | IMPROVED FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | DISPERSOL TECHNOLOGIES, LLC (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016073421-A1 | IMPROVED FORMULATIONS OF VEMURAFENIB AND METHODS OF MAKING THE SAME | DISPERSOL TECHNOLOGIES, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| US-20150132378-A1 | MULTILAYERED DOSAGE FORM | RANBAXY LABORATORIES LIMITED (IN) | 2015-05-14 | — | — | US | claimed |
| US-20140039031-A1 | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-B-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | Dispersol Technologies. LLC (US) | 2014-02-06 | — | — | US | claimed |
| WO-2012116238-A1 | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | DISPERSOL TECHNOLOGIES, LLC (US) | 2012-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091201-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | FECH, PFKP, DUT | GRIK1 4438/4885GRIK2 4550/4885TET2 199/4885 |
| US-20170333404-A1 | IMPROVED FORMULATIONS OF VEMURAFENIB AND METHODS OF MAKING THE SAME | BRAF, PRPF8, NRAS | GRIK1 4749/4885GRIK2 4765/4885TET2 1399/4885 |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HDAC5, HDAC2, HDAC3 | GRIK1 905/4885GRIK2 523/4885TET2 1348/4885 |
| US-11878005-B2 | Formulations of deferasirox and methods of making the same | FECH, PFKP, DUT | GRIK1 4438/4885GRIK2 4550/4885TET2 199/4885 |
| US-20170027911-A1 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | FECH, PFKP, DUT | GRIK1 4438/4885GRIK2 4550/4885TET2 199/4885 |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | HDAC5, HDAC2, HDAC3 | GRIK1 905/4885GRIK2 523/4885TET2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.